Clinical trials: Glucose Response
Postprandial Hyperglycemia
Determination of the PPG and Insulin Responses of Rice Alone and Rice Consumed With Sugardown™
This study was a partly controlled laboratory-based study comparing the short-term postprandial blood glucose and insulin responses produced by 3 test meals containing white rice alone or with SUGARDOWN™ (Galactomannan) in…
- Trial name
- NCT03375398
- Testing
- Rice, Sugardown™
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boston Therapeutics
Type 2 Diabetes Mellitus and Microalbuminuria
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5 mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by randomized, double-blind…
- Trial name
- NCT02332824
- Testing
- TAK-272, Candesartan cilexetil
- Where
- 68 sites in Japan
- Volunteers
- 415 people
- Sponsor
- Takeda
Type 1 Diabetes Mellitus
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
This is an Open-label, randomized study in Type 1 diabetics looking at exposure and response (PK/PD) of TI using GEN2C Inhaler versus rapid acting analog.
- Trial name
- NCT01544881
- Testing
- Technosphere Insulin Inhalation Powder, Rapid Acting Analog
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or…
- Trial name
- NCT00660309
- Testing
- Aliskiren, Irbesartan, Captopril
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Novartis
Insulin Sensitivity, Overweight or Obesity
Pulses Consumption and Its Role in Managing Systemic Inflammation, Insulin Sensitivity and Gut Microbiome in Human
Objective 1: Characterize indices of systemic inflammation and gut microbiota composition and function after chronic (12 weeks) intake of pulses compared to control diet in human OW/OB-IR participants.
- Conditions
- Insulin Sensitivity, Overweight or Obesity, Inflammatory Response
- Trial name
- PS (NCT04267705)
- Testing
- Control, Black bean, Chickpea
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Obesity, Overweight
A Study Investigating the Effects of Neprinol Study Product on Vascular Function
This open-label study investigated the effectiveness of Neprinol on maintaining healthy cardiovascular health in overweight and obese adults. Subjects took 3 capsules, 3 times per day over a period of 12 weeks.
- Trial name
- NCT02862223
- Testing
- Neoprinol
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Postprandial Blood Glucose
Effect of an Arabinogalactan Product
Dietary fiber is an important nutrient that supports gastrointestinal function as well as blood glucose and cholesterol maintenance.
- Trial name
- NCT04005924
- Testing
- arabinogalactan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Biofortis, Merieux NutriSciences
Healthy
fMRI of Hypothalamic Responses to Taste, Temperature and Glucose
The study will consist of five occasions with one week in between. BOLD signal intensity of the hypothalamus will be measured using fMRI.
- Trial name
- COLD-2 (NCT03202342)
- Testing
- Water, Glucose, Ethyl butyrate
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Type 2 Diabetes
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
To evaluate the dose-response relationship of AVE0010 administered once daily and twice daily with chronic dosing in metformin-treated subjects with type 2 diabetes
- Trial name
- NCT00299871
- Testing
- LIXISENATIDE (AVE0010)
- Where
- 7 sites in United States, Brazil and 5 more
- Volunteers
- 542 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus
Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA) approved medications for the treatment of diabetes mellitus.
- Trial name
- NCT00774800
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus, Type 2
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
Insulin resistance (IR) is common in many metabolic disorders and predisposes an individual to Type 2 Diabetes Mellitus (T2DM), the Metabolic Syndrome and coronary atherosclerosis.
- Trial name
- NCT00551564
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
The purpose of this study is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo infusion.
- Trial name
- DEFEND-1 (NCT00678886)
- Testing
- otelixizumab infusion plus physician determined standard of care
- Where
- 109 sites in United States, Canada and 7 more
- Volunteers
- 272 people
- Sponsor
- GlaxoSmithKline
Maximum Observed Plasma Glucose Concentration (Cmax)
Processed Orange and the Glycemic Response
Randomized, placebo controlled, double blind, postprandial crossover study in male subjects. 3 intervention arms, consisting of a control (Product A), a low dose processed whole orange (Product B) and a high dose processed whole…
- Trial name
- POGR (NCT02112851)
- Testing
- Orange flavored beverage
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Type 2 Diabetes
Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes
The purpose of the study is to assess the efficacy response of rivoglitazone HCl compared to pioglitazone HCl on the placebo-corrected change from baseline in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.
- Trial name
- RAISE (NCT00575874)
- Testing
- Rivoglitazone HCl, pioglitazone HCl
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the the dose-response of insulin detemir and insulin NPH in subjects with type 2 diabetes of various race and ethnicity.
- Trial name
- NCT01497600
- Testing
- insulin detemir, insulin NPH
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1
The purpose of the study is to determine whether E1 and G1 are safe and effective in the treatment of type 2 diabetes. Type 2 diabetes is the most common form of diabetes.
- Trial name
- NCT00239187
- Testing
- E1 and G1
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- OPKO Health, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with type 1 diabetes.
- Trial name
- NCT02033239
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Healthy Participants, Healthy Glucose
Royal Ancient Oats™ Study
Evaluating the effects of high avenanthramide ancient oat (Royal Ancient Oats™) muffins versus conventional oat muffins in regard to glycemic control.
- Trial name
- RAO (NCT07371598)
- Testing
- Royal Ancient Oat Flour™
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Standard Process Inc.
Type 2 Diabetes Mellitus
A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00127192
- Testing
- sitagliptin phosphate
- Volunteers
- 363 people
- Sponsor
- Merck Sharp & Dohme LLC